Cellectar biosciences submits phase 1b clinical trial protocol to us food and drug administration for clr 125 to treat triple-negative breast cancer (tnbc)

Good tolerability and robust tumor uptake were observed in tnbc animal models auger emitters offer the potential benefit of enhanced cytotoxicity, safety and ease-of-use florham park, n.j., june 24, 2025 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the company has submitted a protocol with the u.s. food and drug administration (fda) for a phase 1b dose finding study of its auger emitting radiopharmaceutical, clr 125, for the treatment of relapsed tnbc.
CLRB Ratings Summary
CLRB Quant Ranking